GSK-1120212inhibitsMEK1/2andiscurrentlyinclinicaltrialsasapotentialtreatmentformelanoma.GSK-1120212exhibitsanticancerchemotherapeuticactivity,upregulatingp27expressionandinhibitinggrowthincolorectalcancercellsandsuppressingtumorgrowthincolorectalcancerxenografts.
| CasNo. | 871700-17-3 |
|---|---|
| Purity | ≥98% |
| Formula | C26H23FlN5O4 |
| FormulaWt. | 615.39 |
| IUPACName | N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide |
| Synonym | Trametinib,JTP-74057 |
| Solubility | DMSO(10mg/ml) |
| Appearance | WhitePowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| MSDS | G7440MSDSPDF |
|---|---|
| InfoSheet | G7440InfoSheetPDF |
| Brochures | Ras-Raf-MEK-ERKPathwayBooklet |
HartsoughEJ,BasileK,AplinAE.BeneficialEffectsofRAFInhibitorinMutantBRAFSpliceVariant-expressingMelanoma.MolCancerRes.2014Feb11.[Epubaheadofprint].PMID:24520098.
KimKB,KeffordR,PavlickAC,etal.PhaseIIstudyoftheMEK1/MEK2inhibitorTrametinibinpatientswithmetastaticBRAF-mutantcutaneousmelanomapreviouslytreatedwithorwithoutaBRAFinhibitor.JClinOncol.2013Feb1;31(4):482-9.PMID:23248257.
YamaguchiT,KakefudaR,TajimaN,etal.AntitumoractivitiesofJTP-74057(GSK1120212),anovelMEK1/2inhibitor,oncolorectalcancercelllinesinvitroandinvivo.IntJOncol.2011Jul;39(1):23-31.PMID:21523318.
